Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Barrett

Showing results (211-220 of 223) with videos related to

Pageof 23
Sort By:
ACS Infectious Diseases|July 18, 2024
Evaluation of the <i>Leishmania</i> Inositol Phosphorylceramide Synthase as a Drug Target Using a Chemical and Genetic ApproachEdubiel A Alpizar-Sosa, Flavia M Zimbres, Brian S Mantilla, et al.
The Lancet. Infectious Diseases|October 10, 2024
New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidineAndreas K Lindner, Veerle Lejon, Michael P Barrett, et al.
Microsystems & Nanoengineering|September 27, 2021
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detectionValerio F Annese, Samadhan B Patil, Chunxiao Hu, et al.
Plos One|December 10, 2016
Evaluation of Antigens for Development of a Serological Test for Human African TrypanosomiasisSylvain Biéler, Harald Waltenberger, Michael P Barrett, et al.
Plos Pathogens|November 9, 2013
A Trypanosoma brucei kinesin heavy chain promotes parasite growth by triggering host arginase activityGéraldine De Muylder, Sylvie Daulouède, Laurence Lecordier, et al.
ACS Infectious Diseases|December 9, 2020
Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the <i>Leishmania</i> Inositol Phosphorylceramide SynthaseJohn G M Mina, Rebecca L Charlton, Edubiel Alpizar-Sosa, et al.
Plos Pathogens|November 3, 2020
Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugsFederica Giordani, Daniel Paape, Isabel M Vincent, et al.
ACS Infectious Diseases|December 14, 2018
Drug Discovery for Kinetoplastid Diseases: Future DirectionsSrinivasa P S Rao, Michael P Barrett, Glenn Dranoff, et al.
The Journal of Antimicrobial Chemotherapy|November 16, 2013
Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugsJane C Munday, Anthonius A Eze, Nicola Baker, et al.
Nature Microbiology|July 15, 2020
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitorsManuel Saldivia, Eric Fang, Xiaolei Ma, et al.
Pageof 23

Showing results (211-220 of 223) with videos related to

Sort By:
Pageof 23
ACS Infectious Diseases|July 18, 2024
Evaluation of the <i>Leishmania</i> Inositol Phosphorylceramide Synthase as a Drug Target Using a Chemical and Genetic ApproachEdubiel A Alpizar-Sosa, Flavia M Zimbres, Brian S Mantilla, et al.
The Lancet. Infectious Diseases|October 10, 2024
New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidineAndreas K Lindner, Veerle Lejon, Michael P Barrett, et al.
Microsystems & Nanoengineering|September 27, 2021
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detectionValerio F Annese, Samadhan B Patil, Chunxiao Hu, et al.
Plos One|December 10, 2016
Evaluation of Antigens for Development of a Serological Test for Human African TrypanosomiasisSylvain Biéler, Harald Waltenberger, Michael P Barrett, et al.
Plos Pathogens|November 9, 2013
A Trypanosoma brucei kinesin heavy chain promotes parasite growth by triggering host arginase activityGéraldine De Muylder, Sylvie Daulouède, Laurence Lecordier, et al.
ACS Infectious Diseases|December 9, 2020
Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the <i>Leishmania</i> Inositol Phosphorylceramide SynthaseJohn G M Mina, Rebecca L Charlton, Edubiel Alpizar-Sosa, et al.
Plos Pathogens|November 3, 2020
Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugsFederica Giordani, Daniel Paape, Isabel M Vincent, et al.
ACS Infectious Diseases|December 14, 2018
Drug Discovery for Kinetoplastid Diseases: Future DirectionsSrinivasa P S Rao, Michael P Barrett, Glenn Dranoff, et al.
The Journal of Antimicrobial Chemotherapy|November 16, 2013
Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugsJane C Munday, Anthonius A Eze, Nicola Baker, et al.
Nature Microbiology|July 15, 2020
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitorsManuel Saldivia, Eric Fang, Xiaolei Ma, et al.
Pageof 23